|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UGT1A6 |
Gene summary for UGT1A6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UGT1A6 | Gene ID | 54578 |
| Gene name | UDP glucuronosyltransferase family 1 member A6 | |
| Gene Alias | GNT1 | |
| Cytomap | 2q37.1 | |
| Gene Type | protein-coding | GO ID | GO:0006063 | UniProtAcc | P19224 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54578 | UGT1A6 | LZE2T | Human | Esophagus | ESCC | 1.80e-11 | 8.56e-01 | 0.082 |
| 54578 | UGT1A6 | LZE4T | Human | Esophagus | ESCC | 1.68e-41 | 1.18e+00 | 0.0811 |
| 54578 | UGT1A6 | LZE7T | Human | Esophagus | ESCC | 9.32e-08 | 3.83e-01 | 0.0667 |
| 54578 | UGT1A6 | LZE8T | Human | Esophagus | ESCC | 3.19e-08 | 3.17e-01 | 0.067 |
| 54578 | UGT1A6 | LZE20T | Human | Esophagus | ESCC | 2.95e-06 | 2.82e-01 | 0.0662 |
| 54578 | UGT1A6 | LZE22T | Human | Esophagus | ESCC | 1.40e-06 | 5.15e-01 | 0.068 |
| 54578 | UGT1A6 | LZE24T | Human | Esophagus | ESCC | 2.62e-15 | 4.62e-01 | 0.0596 |
| 54578 | UGT1A6 | LZE21T | Human | Esophagus | ESCC | 1.37e-06 | 3.87e-01 | 0.0655 |
| 54578 | UGT1A6 | P1T-E | Human | Esophagus | ESCC | 7.43e-09 | 4.15e-01 | 0.0875 |
| 54578 | UGT1A6 | P4T-E | Human | Esophagus | ESCC | 1.81e-35 | 8.12e-01 | 0.1323 |
| 54578 | UGT1A6 | P8T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.43e-01 | 0.0889 |
| 54578 | UGT1A6 | P9T-E | Human | Esophagus | ESCC | 3.42e-28 | 6.93e-01 | 0.1131 |
| 54578 | UGT1A6 | P10T-E | Human | Esophagus | ESCC | 3.90e-66 | 1.15e+00 | 0.116 |
| 54578 | UGT1A6 | P11T-E | Human | Esophagus | ESCC | 6.74e-09 | 3.76e-01 | 0.1426 |
| 54578 | UGT1A6 | P12T-E | Human | Esophagus | ESCC | 4.19e-82 | 1.72e+00 | 0.1122 |
| 54578 | UGT1A6 | P15T-E | Human | Esophagus | ESCC | 1.05e-90 | 2.63e+00 | 0.1149 |
| 54578 | UGT1A6 | P20T-E | Human | Esophagus | ESCC | 8.24e-04 | 1.34e-01 | 0.1124 |
| 54578 | UGT1A6 | P21T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.14e-01 | 0.1617 |
| 54578 | UGT1A6 | P22T-E | Human | Esophagus | ESCC | 6.76e-78 | 1.28e+00 | 0.1236 |
| 54578 | UGT1A6 | P23T-E | Human | Esophagus | ESCC | 5.34e-19 | 5.54e-01 | 0.108 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:00714662 | Liver | HCC | cellular response to xenobiotic stimulus | 93/7958 | 177/18723 | 4.35e-03 | 1.89e-02 | 93 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UGT1A6 | SNV | Missense_Mutation | c.1180N>T | p.Gly394Cys | p.G394C | P19224 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| UGT1A6 | SNV | Missense_Mutation | rs367897068 | c.1181N>T | p.Gly394Val | p.G394V | P19224 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| UGT1A6 | SNV | Missense_Mutation | c.220N>G | p.Thr74Ala | p.T74A | P19224 | protein_coding | tolerated(0.07) | benign(0.073) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| UGT1A6 | SNV | Missense_Mutation | rs546429827 | c.16N>T | p.Arg6Cys | p.R6C | P19224 | protein_coding | tolerated(0.16) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UGT1A6 | SNV | Missense_Mutation | novel | c.836N>T | p.Cys279Phe | p.C279F | P19224 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| UGT1A6 | SNV | Missense_Mutation | c.1320N>A | p.Met440Ile | p.M440I | P19224 | protein_coding | deleterious(0.02) | benign(0.035) | TCGA-D8-A146-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UGT1A6 | SNV | Missense_Mutation | novel | c.94G>T | p.Val32Phe | p.V32F | P19224 | protein_coding | tolerated(0.06) | benign(0.232) | TCGA-E2-A15T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| UGT1A6 | SNV | Missense_Mutation | rs140613392 | c.1205G>A | p.Arg402His | p.R402H | P19224 | protein_coding | tolerated(0.19) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UGT1A6 | SNV | Missense_Mutation | novel | c.409N>T | p.Asn137Tyr | p.N137Y | P19224 | protein_coding | deleterious(0.01) | benign(0.041) | TCGA-UC-A7PD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| UGT1A6 | SNV | Missense_Mutation | rs115279280 | c.17N>A | p.Arg6His | p.R6H | P19224 | protein_coding | tolerated(0.46) | benign(0) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | daunorubicin | DAUNORUBICIN | ||
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | febuxostat | FEBUXOSTAT | 27798726 | |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | risperidone | RISPERIDONE | ||
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | phenytoin | PHENYTOIN | 26049587 | |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | methotrexate | METHOTREXATE | 29791011 | |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | phenobarbital | PHENOBARBITAL | 26049587 | |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | allopurinol | ALLOPURINOL | 27798726 | |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | SN-38 | 7-ETHYL-10-HYDROXYCAMPTOTHECIN | ||
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | acetaminophen | ACETAMINOPHEN | 23279026,17164591,23462933,26049587,16696573,15761113,11714888 | |
| 54578 | UGT1A6 | ENZYME, DRUGGABLE GENOME | aspirin | ASPIRIN |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |